ESC 365 - Utilising mavacamten to mitigate post TAVR suicide left ventricle risk in patient with concomitant severe aortic stenosis, hypertrophic obstructive cardiomyopathy, and severe coronary artery disease.

ESC2025 Premium Access

Utilising mavacamten to mitigate post TAVR suicide left ventricle risk in patient with concomitant severe aortic stenosis, hypertrophic obstructive cardiomyopathy, and severe coronary artery disease.

Session: Hypertrophic cardiomyopathy: challenges in diagnosis and treatments

Topic: Clinical

Speaker: Doctor C. Mew (Brisbane, AU)

Event: ESC Congress 2025

Congress Presentation

Add to my library

About the speaker

Doctor Christina Mew

Queensland Health, Brisbane (Australia)

2 presentations

0 follower

4 more presentations in this session

Hypertrophic cardiomyopathy in a Mexican female with Fabry disease: challenges in multidisciplinary diagnosis. family with novel pathogenic GLA gene variants.

Speaker: Doctor J. Garcia Diaz (Zapopan, MX)

Morgagni-Adam-Stokes syndrome as first manifestation of Anderson-Fabry disease

Speaker: Doctor G. Marchionni (Rome, IT)

Red flags plays a significant role in the diagnosis of Anderson–Fabry disease

Speaker: Miss A. Yang (Hangzhou, CN)

Connecting the dots in a young patient with left ventricular hypertrophy, diabetes and deafness

Speaker: Doctor A. Papageorgiou (Athens, GR)

Access the full session

Hypertrophic cardiomyopathy: challenges in diagnosis and treatments

Speakers: Doctor C. Mew, Doctor J. Garcia Diaz, Doctor G. Marchionni, Miss A. Yang, Doctor A. Papageorgiou

About the event

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress

ESC 365 is supported by

bristol-myers-squibb

Explore sponsored resources

novartis

Explore sponsored resources